Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-09-2021 | Positron Emission Tomography | Original Article

First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸F]FNDP PET

Authors: Jennifer M. Coughlin, Stephanie Slania, Yong Du, Laura K. Shinehouse, Mary Katherine Brosnan, Babak Behnam Azad, Daniel P. Holt, Hong Fan, Wojciech G. Lesniak, Il Minn, Steven P. Rowe, Robert F. Dannals, Andrew G. Horti, Martin G. Pomper

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 10/2021

Abstract

Purpose

Soluble epoxide hydrolase (sEH) is an enzyme with putative effect on neuroinflammation through its influence on the homeostasis of polyunsaturated fatty acids and related byproducts. sEH is an enzyme that metabolizes anti-inflammatory epoxy fatty acids to the corresponding, relatively inert 1,2-diols. A high availability or activity of sEH promotes vasoconstriction and inflammation in local tissues that may be linked to neuropsychiatric diseases. We developed [¹⁸F]FNDP to study sEH in vivo with positron emission tomography (PET).

Methods

Brain PET using bolus injection of [¹⁸F]FNDP followed by emission imaging lasting 90 or 180 min was completed in healthy adults (5 males, 2 females, ages 40–53 years). The kinetic behavior of [¹⁸F]FNDP was evaluated using a radiometabolite-corrected arterial plasma input function with compartmental or graphical modeling approaches.

Results

[¹⁸F]FNDP PET was without adverse effects. Akaike information criterion favored the two-tissue compartment model (2TCM) in all ten regions of interest. Regional total distribution volume (V_T) values from each compartmental model and Logan analysis were generally well identified except for corpus callosum V_T using the 2TCM. Logan analysis was assessed as the choice model due to stability of regional V_T values from 90-min data and due to high correlation of Logan-derived regional V_T values with those from the 2TCM. [¹⁸F]FNDP binding was higher in human cerebellar cortex and thalamus relative to supratentorial cortical regions, which aligns with reported expression patterns of the epoxide hydrolase 2 gene in human brain.

Conclusion

These data support further use of [¹⁸F]FNDP PET to study sEH in human brain.

Available only for authorised users

Zarriello S, Tuazon JP, Corey S, Schimmel S, Rajani M, Gorsky A, et al. Humble beginnings with big goals: small molecule soluble epoxide hydrolase inhibitors for treating CNS disorders. Prog Neurobiol. 2019;172:23–39. https://doi.org/10.1016/j.pneurobio.2018.11.001.CrossRefPubMed

Hung YW, Hung SW, Wu YC, Wong LK, Lai MT, Shih YH, et al. Soluble epoxide hydrolase activity regulates inflammatory responses and seizure generation in two mouse models of temporal lobe epilepsy. Brain Behav Immun. 2015;43:118–29. https://doi.org/10.1016/j.bbi.2014.07.016.CrossRefPubMed

Ren Q, Ma M, Ishima T, Morisseau C, Yang J, Wagner KM, et al. Gene deficiency and pharmacological inhibition of soluble epoxide hydrolase confers resilience to repeated social defeat stress. Proc Natl Acad Sci U S A. 2016;113(13):E1944–E52. https://doi.org/10.1073/pnas.1601532113.CrossRefPubMedPubMedCentral

Ren Q, Ma M, Yang J, Nonaka R, Yamaguchi A, Ishikawa K-I, et al. Soluble epoxide hydrolase plays a key role in the pathogenesis of Parkinson's disease. Proc Natl Acad Sci U S A. 2018;115(25):E5815–E23. https://doi.org/10.1073/pnas.1802179115.CrossRefPubMedPubMedCentral

Horti AG, Wang Y, Minn I, Lan X, Wang J, Koehler RC, et al. 18F-FNDP for PET imaging of soluble epoxide hydrolase. J Nucl Med. 2016;57(11):1817–22. https://doi.org/10.2967/jnumed.116.173245.CrossRefPubMedPubMedCentral

Du Y, Minn I, Foss C, Lesniak WG, Hu F, Dannals RF, et al. PET imaging of soluble epoxide hydrolase in non-human primate brain with [(18)F]FNDP. EJNMMI Res. 2020;10(1):67. https://doi.org/10.1186/s13550-020-00657-7.CrossRefPubMedPubMedCentral

Azad BB, Holt DP, Ravert HT, Horti AG, Dannals RF. An optimized radiosynthesis of [(18) F]FNDP, a positron emission tomography radiotracer for imaging soluble epoxide hydrolase (sEH). Journal of Labelled Compounds & Radiopharmaceuticals. 2018;61(7):567–72. https://doi.org/10.1002/jlcr.3620.CrossRef

Rahmim A, Cheng JC, Blinder S, Camborde ML, Sossi V. Statistical dynamic image reconstruction in state-of-the-art high-resolution PET. Phys Med Biol. 2005;50(20):4887–912. https://doi.org/10.1088/0031-9155/50/20/010.CrossRefPubMed

Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. Journal of Cerebral Blood Flow and Metabolism. 2007;27(9):1533–9. https://doi.org/10.1038/sj.jcbfm.9600493.CrossRefPubMed

10.

Logan J, Fowler JS, Volkow ND, Wolf AP, Dewey SL, Schlyer DJ, et al. Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. Journal of Cerebral Blood Flow and Metabolism. 1990;10(5):740–7. https://doi.org/10.1038/jcbfm.1990.127.CrossRefPubMed

11.

Glatting G, Kletting P, Reske SN, Hohl K, Ring C. Choosing the optimal fit function: comparison of the Akaike information criterion and the F-test. Med Phys. 2007;34(11):4285–92. https://doi.org/10.1118/1.2794176.CrossRefPubMed

12.

Golla SSV, Adriaanse SM, Yaqub M, Windhorst AD, Lammertsma AA, van Berckel BNM, et al. Model selection criteria for dynamic brain PET studies. EJNMMI Physics. 2017;4(1):30. https://doi.org/10.1186/s40658-017-0197-0.CrossRefPubMedPubMedCentral

13.

Sjostedt E, Zhong W, Fagerberg L, Karlsson M, Mitsios N, Adori C, et al. An atlas of the protein-coding genes in the human, pig, and mouse brain. Science (New York, NY). 2020;367(6482):eaay5947. https://doi.org/10.1126/science.aay5947.CrossRef

Title: First-in-human neuroimaging of soluble epoxide hydrolase using [18F]FNDP PET
Authors: Jennifer M. Coughlin
Stephanie Slania
Yong Du
Laura K. Shinehouse
Mary Katherine Brosnan
Babak Behnam Azad
Daniel P. Holt
Hong Fan
Wojciech G. Lesniak
Il Minn
Steven P. Rowe
Robert F. Dannals
Andrew G. Horti
Martin G. Pomper
Publication date: 01-09-2021
Publisher: Springer Berlin Heidelberg
Keyword: Positron Emission Tomography
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 10/2021
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-021-05231-4

2024 ASCO Annual Meeting

Springer Medicine

First-in-human neuroimaging of soluble epoxide hydrolase using [¹⁸F]FNDP PET

Abstract

Purpose

Methods

Results

Conclusion

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 10/2021

Synthesis and preclinical evaluation of [11C]MTP38 as a novel PET ligand for phosphodiesterase 7 in the brain

18F-Boramino acid PET/CT in healthy volunteers and glioma patients

Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging

Long COVID hallmarks on [18F]FDG-PET/CT: a case-control study

Baseline PET/CT imaging parameters for prediction of treatment outcome in Hodgkin and diffuse large B cell lymphoma: a systematic review

First-in-human study of an 18F-labeled boramino acid: a new class of PET tracers